We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)


Parsortix FDA clearance marks a key transition point

Lighthouse | 26 May 2022

Futura Medical

Major MED3000 deal for Europe with Cooper Health

Lighthouse | 23 May 2022


Robust Cell Therapy performance lifts FY22 guidance

Lighthouse | 23 May 2022


FY21 results: prepared for commercial success

Lighthouse | 28 April 2022

Futura Medical

FY21 results reassure on cash runway and hint at EU deal

Lighthouse | 26 April 2022

Arecor Therapeutics

Ambitious, focussed, and delivering on its promise

Update | 25 April 2022


A fresh impetus in delivering immune-oncology vaccines

Outlook | 12 April 2022


Sustained FY21 growth with significantly more potential

Update | 06 April 2022


FY21 results: a year of frustrations and opportunities

Update | 06 April 2022

Redx Pharma

RXC008 nominated as GI-ROCK drug candidate

Lighthouse | 30 March 2022
< 4 5 6 7 8 9 10 11 12 13 >
385 results found.